Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme found in all living cells, essential for energy metabolism and a variety of regulatory processes [1, 2]. It exists in two forms: an oxidized form (NAD+) and a reduced form (NADH), acting as a key electron carrier in redox reactions such as glycolysis and the citric acid cycle [2]. Beyond its role in metabolism, NAD+ serves as a critical substrate for enzymes like sirtuins, poly(ADP-ribose) polymerases (PARPs), and cADP-ribose synthases (e.g., CD38), which regulate DNA repair, gene expression, and calcium signaling [3, 4]. Systemic decline in NAD+ levels is associated with aging and various age-related pathologies, including neurodegenerative diseases, metabolic disorders, and cardiovascular decline [3, 4]. Consequently, therapeutic strategies aim to restore NAD+ levels through precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) or by inhibiting NAD+-consuming enzymes like CD38 [5, 6, 9]. Conversely, in oncology, inhibiting NAD+ biosynthesis (e.g., via NAMPT inhibitors) is explored to starve cancer cells of energy and DNA repair capacity [7, 8]. Citations: [1] Bogan KL, Brenner C. Annu Rev Nutr. 2008;28:115-30. [2] Cantó C, et al. Cell Metab. 2015;22(1):31-53. [3] Verdin E. Science. 2015;350(6265):1208-13. [4] Imai S, Guarente L. Trends Cell Biol. 2014;24(8):464-71. [5] Martens CR, et al. Nat Commun. 2018;9(1):1286. [6] Yoshino J, et al. Cell Metab. 2011;14(4):528-36. [7] Lord CJ, Ashworth A. Science. 2017;355(6330):1152-1158. [8] Nahimana A, et al. Blood. 2009;113(14):3276-86. [9] Escande C, et al. Diabetes. 2013;62(4):1084-93.
Modulation of NAD+ levels through precursor supplementation (NR, NMN), inhibition of NAD+ salvage pathways (NAMPT inhibitors), inhibition of NAD+ degradation (CD38 inhibitors), or competitive inhibition of NAD+-dependent enzymes (PARP inhibitors).
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinamide adenine dinucleotide (NAD+) (NAD+).